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tings. Descriptive statistics were used to look at items of interest. Results: There 
were 1403 discharges meeting the inclusion criterion. These were linked to 1402 ER 
discharges previous to the surgery. There were no significant differences between 
the genders in terms of characteristics like race, primary payer, age, etc. However, 
more men had ER visits than women (52.43% vs 47.57%). The top diagnosis in the 
ER consisted of conduction disorders (21.03%). Syncope occurred in 10.05% of dis-
charges. Atrial fibrillation was the only ER diagnosis which women experienced 
more than men. ConClusions: The findings of the study were inconclusive in 
showing significant differences between the genders in terms of characteristics 
and ER diagnosis among recipients of primary pacemaker.
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objeCtives: To estimate low-density lipoprotein cholesterol (LDL-C) goal attainment 
in patients with hyperlipidemia or prior cardiovascular (CV) events. Methods: 
Retrospective population-based cohort study conducted using electronic medical 
records linked to national registers. Patients were included in the study based on a 
prescription of lipid-lowering treatment between January 1, 2006 and December 31, 
2006 or history of CV events (prior to 2006) and followed until December 31, 2012 for 
estimation of LDL-C goal attainment. Patients were stratified into cohorts based on 
CV risk level. Propensity score matching was applied to compare patients with new 
events (myocardial infarction, unstable angina, revascularization, ischemic stroke, 
transient ischemic attack or heart failure) to patients without new events. Results: 
Mean LDL-C at the time of the new CV event (index date) was 100.4 mg/dL for 
patients with CV event history who had a new event (n= 1,101). The mean LDL-C 
for patients without new events in the same cohort (n= 1,304) was 97.4 mg/dL. The 
proportion of patients with CV event history and LDL-C < 70 mg/dL was 20.5% and 
21.5% for patients with and without new events, respectively. The percentage who 
attained the goal of 100 mg/dL was 54.1% and 58.1%, respectively. Mean LDL-C for 
CV risk equivalent (RE) patients with new events (n= 803) was 100.3 mg/dL while 
patients in the same cohort without new events (n= 975) had a mean level of 97.4 mg/
dL. 22.0% of CV RE patients with new events had a LDL-C < 70 mg/dL and 53.8% had 
a level < 100 mg/dL. The corresponding data for CV RE patients without new events 
were 19.1% and 57.7%, respectively. ConClusions: The proportion of patients who 
met LDL-C goals was low, suggesting that current treatment is suboptimal. The pro-
portion of patients who attained the goals was similar in patients with and without 
new events and across CV risk levels.
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objeCtives: To estimate the clinical impact over three years of switching atrial 
fibrillation (AF) patients receiving no treatment or aspirin, or Vitamin K antago-
nist (VKA), to rivaroxaban in China. Methods: A prevalence-based, deterministic 
budget impact model was developed. The number of AF patients was calculated 
based on data from literatures. The baseline risk of events and the efficacy and 
safety data for aspirin and VKA were from meta-analysis. While the efficacy and 
safety data for rivaroxaban were from ROCKET-AF trial. The current treatment pat-
tern was from a large registry study for Chinese AF patients. 9%, 61% and 30% of AF 
patients received no treatment, aspirin and VKA, respectively. We just assumed that 
5% of the patients who received aspirin currently switch to rivaroxaban per year. 
Then the model estimates the number of ischemic stroke (IS), systemic embolisms 
(SE), myocardial infarction (MI), intracranial bleeds (ICH) and major extracranial 
bleeds (ECH) per year. Results: The number of NVAF patients is 4.5 million. For 
those patients, there might be 127,469 major IS events, 34,001 SE events, 9,933 MI 
events, 28,745 ICH events and 56,193 major ECH events under current treatment 
per year. With 5% patients switching to rivaroxaban from aspirin in the first year, 
the IS events reduced 4%, SE events reduced 6% and MI events reduced 2% with 
increased 3% ICH and 1% ECH. To the third year, the IS events continue to reduce 
11%, SE events reduced 17% and MI events reduced 6% with increased 10% ICH and 
4% ECH compared with the current situation. ConClusions: Rivaroxaban may 
decrease the clinical burden of AF in China by reducing the incidence of stroke and 
fatal CV events. Decision-makers can find the exact value of rivaroxaban easily by 
the simple tool in different situations.
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objeCtives: To estimate the clinical impact over three years of switching deep 
vein thrombosis (DVT) patients receiving low molecular weight heparin (LMWH) 
and vitamin K antagonist (VKA) to rivaroxaban. Methods: A prevalence-based, 
deterministic budget impact model was developed. The incidence of DVT patient 
was from literatures. We assumed that 12%, 65% and 23% received treatment for 
3months, 6months and 12months, separately. The efficacy and safety data for 
LMWH+VKA were from meta-analysis. While the efficacy and safety data for rivar-
oxaban were from EINSTEIN-DVT trial. We just assumed that 20% of the patients 
who received LMWH + VKA currently switch to rivaroxaban in the first year and 
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objeCtives: Following an acute deep vein thrombosis (DVT) or pulmonary 
embolism (PE) event, physicians can choose among heparin, vitamin K antago-
nists (VKA), and Non-VKA oral anticoagulants (NOAC) for therapy. We assessed 
patients’ satisfaction with their ongoing anticoagulation treatment. Methods: 
PREFER in VTE (PREvention oF thromboembolic events – European Registry in 
Venous Thromboembolism) is an ongoing non-interventional study in France, 
Germany, Austria, Switzerland, Italy, Spain and UK. The Perception of Anti-Coagulant 
Treatment Questionnaire (PACT-Q2) is a valid and reliable instrument that allows 
the assessment of patients’ satisfaction regarding anticoagulant treatment, as well 
as their opinion about convenience of use. Results: At baseline (BL), a total of 
2311 patients with acute VTE (1366 DVT, 945 PE) met the eligibility criterion of cur-
rent anticoagulation and completed the PACT-Q2 questionnaire. 665 patients were 
eligible for an interim analysis at 6 months: 7.8% have received heparin only, 33.2% 
initial heparin/VKA and 9.0% uninterrupted NOAC. In the “convenience” dimen-
sion, the score (0-100 range) at BL/6 months was 78.9 ±17.62/ 76.2 ±18.20 points for 
heparin only, 81.0 ±16.36/ 80.5 ±16.34 for heparin/VKA, and 88.9 ±12.14/ 93.3 ±7.30 for 
NOACs (all patients: 81.5 ±16.78/ 81.6 ±17.26). Compared to BL, the score improved 
the most in the NOAC group. In the “anticoagulant treatment satisfaction” dimen-
sion, the score at BL/ 6- month was 64.2 ±14.02/64.3 ±16.68 points for heparin only, 
65.8 ±14.92/68.7 ±14.46 for heparin/VKA and 68.2 ±16.65/72.9 ±16.70 for NOACs (all 
patients 65.4 ±15.26/68.5 ±15.76). ConClusions: Overall, patients on current anti-
coagulation reached relatively high values on the convenience scale, but moderate 
values on the satisfaction scale. Patients on NOACs rated their convenience and 
treatment satisfaction substantially higher than patients on heparin/VKA.
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objeCtives: We aimed to understand treatment satisfaction over time under eve-
ryday practice conditions after introduction of NOACs (Non vitamin K antagonist 
oral anticoagulants) in the The PREvention oF thromboembolic events – European 
Registry in Atrial Fibrillation (PREFER in AF). Methods: PREFER in AF documents 
clinical characteristics, management, quality of life and other outcome parameters 
of AF patients. A total of 6412 consecutive patients with ECG-confirmed AF in the 
previous 12 months were followed up prospectively. The ‘Perception of Anticoagulant 
Treatment Questionnaire’ is a valid and reliable instrument to assess patients’ 
expectations (PACT-Q1) and satisfaction regarding anticoagulant treatment, as 
well as patients’ opinion about treatment convenience of use (PACT-Q2). Results: 
A total of 2985 patients were willing to fill out the PACT-Q2 questionnaire both at 
baseline and FU. 1632 of these were on vitamin K antagonists (VKAs), 374 on NOACs, 
203 on antiplatelets (AP), 142 on VKA+AP combinations and 634 on neither treat-
ment. In the “convenience” dimension, the overall score (0-100 range) at FU was 
84.3 ±16.5. The scores ranged from 81.9 in the no NOAC/VKA/AP group (± 18.43), 
84.0 AP (± 16.7), 84.4 NOAC (± 15.9), 85.0 VKA (± 15.9) to 86.8 in the VKA +AP group 
(± 14.13). In the “anticoagulant treatment satisfaction” dimension of the PACT-Q2, 
the overall score was 65.1 ±15.7. The scores ranged from 64.5 in no NOAC/VKA/AP 
(± 14.8), 63.2 in AP group (± 17), 66.0 in NOAC (± 15.05), 64.9 in VKA (± 15.9), to 69.5 in 
VKA +AP group (± 15.8). ConClusions: Overall, patients on current anticoagulation 
achieve relatively high values on the convenience scale, but moderate values on the 
satisfaction scale. While differences in group size and patient characteristics need to 
be taken into account, patients on NOACs compared to patients on VKAs rate their 
convenience and treatment comparable to other treatment schemes.
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objeCtives: Men’s and Women’s health care experiences differ as they age. These 
differences lead to disparate health and treatment outcomes between the genders, 
especially in the area of cardiac health, which has significant disease burden in 
the US. Women experience symptoms that ‘deviate’ from the ones found in a clini-
cian’s guidebook. The emergency room (ER) also serves as a medical space for initial 
diagnosis of heart conditions. Thus, looking at the gender based use of ER prior to 
a cardiac event may help us understand the disparities from a systems perspec-
tive. Cardiac pacemakers are used to treat severe and/or symptomatic bradycardia, 
heart block or a combination of both. This study explored gender differences in 
characteristics and ER diagnoses associated with pacemaker implants in an inpa-
tient setting. Methods: The study used data from the inpatient and emergency 
room hospital discharge data from the Florida HealthCare Utilization Project for 
years 2009 and 2010. Patients with a primary insertion of initial pacemaker and 
with a diagnosis of bradycardia or heart block or both were included. A unique 
patient identifier helped map patients across the inpatient and emergency set-
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ing to attitudes and beliefs relevant to the therapy area. Results: Quantitative 
segmentation identified key distinct segments of payers displaying unique atti-
tudes and beliefs towards entry of the novel class of anticoagulation agents. The 
segmentation approach identified key differentiating factors between segments, 
allowing full profiling of each group. Payers’ underlying values were explored 
with a view to gain insight to what is important to them as individuals as well as 
decision makers, what motivates them and what restricts them. ConClusions: 
Findings from this research were utilized to prioritise targeting of payer segments. 
In addition, communication and messaging strategies were optimised for these 
payer groups. Subsequently a post-project feedback workshop with the pharma-
ceutical client was conducted. The poster will discuss how the research was used 
by the pharmaceutical client and the benefits of this strategic tool to the brand 
team.
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objeCtives: To assess whether the prescribing pattern of statins changed after 
reimbursement criteria revision and regional policies in a general practice in 
southern Italy. Methods: Analysis has been performed on a database of 123 
medical practitioners that have managed an average of 190.000 inhabitants in 
the Campania Region (south of Italy). Prevalence of use and incidence of new 
treatments were calculated from Jan 2012 to Jun 2013. Statin users were stratified 
into three groups (Moderate Cardiovascular Risk, MR; High Cardiovascular Risk, 
HR; Very High Cardiovascular Risk, VHR) according to new criteria for reimburse-
ment for lipid lowering agents revised by the Italian Drug Agency (AIFA) (Nota 13).  
Results: After the reimbursement criteria revision (November 2012), the prev-
alence of statin use slightly decreased reaching 6.6% in the second quarter of 
2013 (-14% compared to second quarter of 2012). Stratified by level of CV risk, the 
prevalence of statin use is reduced by 24.9% into MR, 13.1% into HR and 5.9% into 
VHR, while incidence of new users of 22.4%, 34 5% and 45.8% respectively. In the 
second quarter of 2013, atorvastatin (+45.3%) was prescribed in 57,5% of patients 
in MR group (+45.3%), rosuvastatin 5.9% with (-60.1%) and 1.6% with simvasta-
tin + ezetimide (-57.5%); in HR group, 40.7% (+20.8) atorvastatin, 5.3% (-57.0%) 
rosuvastatin and 2.1% (- 42.3%) simvastatin + ezetimide; in VHR, 56.3% (+15.8) 
atorvastatin, 12.5% (-37.5%) rosuvastatin and 2.1% (-27.1%) simvastatin + ezetim-
ide. ConClusions: The revision of reimbursement criteria and the regional poli-
cies led to significant changes in general practice in southern Italy resulting in a 
reduction in the statin use, especially in patients who could potentially benefit 
from it most. The results of the study provide useful information for the general 
practitioner about areas for improvement prescriptive.
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objeCtives: Frequent legislative changes that have brought the Slovak health care 
reform over the past decade, reflected also on drug policy and especially on the 
prices of medicines and total consumption of medicines. Generic substitution was 
introduced to save both health insurance and patient’s finances. Methods: Data 
on prices and consumption of lipid-lowering agent medicines were collected from 
Slovak Ministry of Health and Health insurance. Data processing, we used a uniform 
methodology recommended by the WHO - ATC / DDD classification and basic statisti-
cal methods of observing. In case of national data, we reported consumption in units 
of DDD per 1,000 inhabitants for one day (DID). Results: A class of lipid-lowering 
agent medicines (C10A) poses in recent years on Slovak market expanding group. Its 
number significantly increased in direct proportion with the introduction of generic 
drugs, mainly after 2004, when generic substitution was enacted and later after 
2011, when mandatory generic prescribing entry into the force. The proportion of 
total medicines and generic drugs in the group C10A were x2008total-medicines/%generic-
drugs= 55/74,6 types and x2014total-medicines/%generic-drugs= 203/94 types. The number of 
generic drugs with atorvastatin ranged x2008-2014= 4-18, rosuvastatin x2008-2014= 3-11, 
simvastatin x2008-2014= 7-7, fluvastatin x2008-2014= 1-1, lovastatin x2008-2014= 1-5. The 
consumption of medicines with atorvastatin x2008-2014-packages= +Δ 47,7%, x2008-2014-
value= +Δ 20,1% € , rosuvastatin x2008-2014-packages= +Δ 18,8%, x2008-2014-value= -Δ 77,4 % € , 
simvastatin x2008-2014-packages= -Δ 48,6%, x2008-2014-value= -Δ 79,6 % € , fluvastatin x2008-
2014-packages= -Δ 50,5%, x2008-2014-value= -Δ 90,4 % € , lovastatin x2008-2014-packages= -Δ 70,1%, 
x2008-2014-value= -Δ 81,8 % € . In the years 2008-2013 consumption of C10A in Slovakia 
increased by 77,5 per DDD/1000 inh. /day (DID). OECD statistics from 2011 indicate 
consumption of lipid-lowering agents amounting to 130 DID, while at the end of 
2013 according to our data analysis increased to 142.8 DID. ConClusions: Overall 
changes in legislation of drug policy brought rising utilization of lipid-lowering agent 
medicines and in 2011 Slovakia together with Great Britain was on the second place 
with 130 DID consumption of lipid-lowering agents.
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following with 15% of the rest patients switching to rivaroxaban per year. Then the 
model estimates the number of DVT, pulmonary embolism (PE), intracranial bleeds 
(ICH) and major extracranial bleeds (ECH) per year. Results: The new DVT patients 
are 287,813 per year. For those patients, with 20% patients switching to rivaroxa-
ban from LMWH+VKA in the first year, the recurrent venous thrombus embolism 
(VTE) events, including DVT and PE, reduced 4.6%, major bleeding events including 
ECH and ICH reduced 7% with 1% minor bleeding increasing. To the third year, the 
recurrent VTE events reduced 11.4%, major bleeding events reduced 17% with 2% 
minor bleeding increasing compared with the current situation. ConClusions: 
Rivaroxaban may decrease the clinical burden of DVT in China by reducing the 
incidence of recurrent VTE and fatal bleeding events. Decision-makers can find the 
exact value of rivaroxaban easily by the simple tool in different situations.
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objeCtives: Disease management programs (DMPs) for cardiovascular risk (CVR) 
and chronic obstructive pulmonary disease (COPD) are increasingly implemented 
in the Netherlands to improve quality of care and patient’s lifestyle. The aim of 
the study was to provide evidence about the (cost-) effectiveness of Dutch DMPs 
as implemented in daily practice. Methods: We compared the 2-year costs 
and changes in physical activity, smoking behaviour, and utilities between the 
most and the least comprehensive DMP in four disease categories: primary CVR-
prevention, secondary CVR-prevention, both types of CVR-prevention, and COPD 
(total n: 1034). Propensity score matching increased comparability between DMPs. 
A cost-utility analysis was performed from the health care and societal perspective. 
Sensitivity analysis was performed to estimate the impact of DMP development and 
implementation costs on the cost-effectiveness. Results: Patients in the most 
comprehensive DMPs increased physical activity and had higher smoking cessation 
probabilities after 2 years in most disease categories. From a health care perspec-
tive, the incremental costs were positive in primary CVR-prevention (96% certainty), 
negative in secondary and both types of CVR prevention (93% and 98% certainty) and 
indifferent in COPD. The incremental QALYs were positive in all categories (certainty 
range: 64%-80%). The incremental cost-effectiveness ratio’s ranged from € -114,662 
to € 8,849. The results from the societal perspective and the sensitivity analysis were 
in the same line. ConClusions: The most comprehensive DMPs for CVR and COPD 
were cost-effective compared to the least comprehensive DMPs. The challenge for 
Dutch stakeholders is to find the optimal mixture of interventions.
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objeCtives: This study examines the extent to which Integrated Care Programs 
lead to an improvement in the quality of patient care. The aim of the study is 
to carry out a quantitative analysis of differences in quality between patients 
participating in Disease Management Programs (DMPs) and patients receiving 
regular care, regardless of health insurance status, program, or region. Methods: 
The study used data from the representative IMS Disease Analyzer database. It 
included patients with a confirmed diagnosis of hypertension who started anti-
hypertensive therapy in the period between January 2010 and December 2012. 
The primary dependent variable of the study was the change in blood pressure 
after at least six months of antihypertensive treatment. To assess this variable, we 
determined the proportion of patients with a blood pressure of below 140/90 in the 
period between day 183 and day 365 after initiation of treatment (index date). In 
order to eliminate confounding factors, we performed one-to-one matching based 
on a propensity score. Results: 1,317 patients participating in the integrated 
care program (ICP) and 1,317 patients not participating in such a program were 
available for further analyses following the propensity score matching. Patients 
in both groups were very similar with respect to demographic variables and 
antihypertensive therapy. The proportion of patients with blood pressure values 
< 140/90 after one year of treatment was 33.6% in the group of ICP participants 
and 22.7% in the group of non-ICP patients (p< 0.0001). The chance of reaching 
the treatment goal was significantly higher in the group of patients participating 
in an integrated health program (OR: 1.73; 95% CI: 1.45-2.05). ConClusions: It 
is evident that DMP participants have a significantly better chance of achieving 
the therapy goal. Thus, it can be established that integrated health care programs 
have a positive effect on quality.
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objeCtives: The research aimed to develop an attitudinal based, payer segmen-
tation approach to explore payers’ attitudes and behaviours towards the man-
aged entry of novel agents in the anticoagulation area in the health care systems 
of countries within the EU. The segmentation exercise explored payers’ drivers, 
motivations, barriers and limitations when assessing, endorsing or restricting new 
agents. Methods: Qualitative in-depth telephone interviews were conducted 
to explore payers’ views, along with perceived challenges relating to the entry of 
novel class of anticoagulation agents. Followed by a quantitative data collection 
and advanced statistical analysis methodology was employed with regional and 
local payers in each of the researched markets to define the segmentation accord-
